Randomized Trialhigh evidence
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
Lancet (London, England)·July 28, 2026·PMID 42520828
Why it mattersPAH remains a progressive disease with high morbidity despite dual therapy. Ralinepag offers an oral, once-daily prostacyclin pathway option that significantly delays clinical worsening, potentially filling a gap between current oral therapies and parenteral prostacyclins.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled